About the company

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose tissue. Raziel's prime-candidate, RZL-012, is a first-in-class, currently in clinical development to treat obesity and related disorders. Raziel launched its clinical trial in the US at Q4 2015, expecting final data that include safety and efficacy, by mid of 2016.

Our technology

We become fat because we do not burn enough calories, yet consume extra food. Enhanced thermogenesis (=heat production) can correct this imbalance. Thermogenesis in large animals is different than that of small rodents and Raziel carefully verified that its drug acts in small and large mammals as well. Raziel's novel drug is able to convert energy-storing white-adipose-tissue (WAT) into energy-burning brown-like adipose tissue, as evident by histological, cellular and molecular studies. Moreover, the physiological outcome of this tissue-remodeling is an outstanding local thermogenesis as clearly demonstrated in human-size pigs. This thermogenesis lasts for several months following a single treatment, with the ensuing ~30-50% reduction in s.c. fat at the treated site. The molecular target of Raziel proprietary drug was also identified and is part of Raziel IP.

Contact details

alon@raziel-therapy.com

www.raziel-therapy.com
Keren-Or Amar  
VP, Business Development, Healthcare

Yissum Research Development Company of the Hebrew University of Jerusalem  
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem  
P.O. Box 39135, Jerusalem 91390 Israel  
Telephone: 972-2-658-6688, Fax: 972-2-658-6689